A Phase 1 interventional study of Moxidectin in Onchocerciasis, sponsored by Medicines Development for Global Health. Completed at 1 site in Ghana. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-09-05.
Sponsored by Medicines Development for Global Health · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary purpose of this study is to determine a dose of moxidectin for children 4 to 11 years that is equivalent to an 8 mg dose administered for treatment of onchocerciasis in people 12 years and over. The secondary purpose is to evaluate the safety and pharmacokinetics of a single dose of moxidectin in children and adolescents aged 4 to 17 years.
35 studies on the registry are indexed under Onchocerciasis; 7 are open to participants now.
This study's enrollment of 36 is below the median of 216 across 26 interventional studies indexed under Onchocerciasis.
Browse Onchocerciasis studies →Medicines Development for Global Health is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Aged 4 to 17 years, inclusive:
Exclusion Criteria:
Weight:
Clinically relevant laboratory abnormalities at Screening, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Moxidectin 8mg per oral, single dose
Drug: Moxidectin
Moxidectin 8mg (or lower dose) per oral, single dose
Drug: Moxidectin
Moxidectin single dose, determined by population pharmacokinetic modelling including data from Cohorts 1 and 2
Drug: Moxidectin
2 mg tablets
Area Under the Plasma Concentration Versus Time Curve of Moxidectin.
Moxidectin concentration in plasma collected at pre-specified intervals after dosing with oral moxidectin determined using a validated liquid chromatography-mass spectrometry(MS)/MS method.
Time frame: Pre-dose (Screening) and post-dose at Hours 1, 2, 4, 8, 24 and 72 and Days 7, 14 and 28.
Area Under the Concentration Versus Time Curve (Zero to Infinity) of Moxidectin
Moxidectin concentration in plasma collected at pre-specified intervals after dosing with oral moxidectin determined using a validated liquid chromatography-mass spectrometry(MS)/MS method.
Time frame: Pre-dose (Screening) and post-dose at Hours 1, 2, 4, 8, 24 and 72, Days 7, 14 and 28 and Week 12.
Maximum Observed Plasma Concentrations (Cmax) of Moxidectin
Moxidectin concentration in plasma collected at pre-specified intervals after dosing with oral moxidectin determined using a validated liquid chromatography-mass spectrometry(MS)/MS method.
Time frame: Pre-dose (Screening) and post-dose at Hours 1, 2, 4 and 8.
Incidence and Severity of Adverse Events.
Incidence and severity of adverse events, assessed by the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Paediatric Adverse Events, Version 2.1.
Time frame: Day 0 to Week 24 inclusive.
The first participant was screened on 29 March 2021 and the last participant last study visit was completed on 28 September 2022. Participants were recruited from communities in the Kpassa sub-district of the Oti region in Ghana, which is endemic for onchocerciasis.
| Milestone | 12 to 17 Years MOX 8 mg | 8 to 11 Years MOX 8 mg | 8 to 11 Years MOX 6 mg | 4 to 7 Years MOX 4 mg |
|---|---|---|---|---|
| Started | 9 | 9 | 9 | 9 |
| Completed | 9 | 9 | 9 | 9 |
| Not completed | 0 | 0 | 0 | 0 |
Moxidectin concentration in plasma collected at pre-specified intervals after dosing with oral moxidectin determined using a validated liquid chromatography-mass spectrometry(MS)/MS method.
| (hr*ng/mL)/mg | 12 to 17 Years MOX 8 mg | 8 to 11 Years MOX 6 mg | 8 to 11 Years MOX 8 mg | 4 to 7 Years MOX 4 mg |
|---|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve of Moxidectin. | 2680 ± 24.7 | 2230 ± 52.3 | 3310 ± 23.0 | 1880 ± 26.5 |
Moxidectin concentration in plasma collected at pre-specified intervals after dosing with oral moxidectin determined using a validated liquid chromatography-mass spectrometry(MS)/MS method.
| (hr*ng/mL)/mg | 12 to 17 Years MOX 8 mg | 8 to 11 Years MOX 6 mg | 8 to 11 Years MOX 8 mg | 4 to 7 Years MOX 4 mg |
|---|---|---|---|---|
| Area Under the Concentration Versus Time Curve (Zero to Infinity) of Moxidectin | 3140 ± 24.8 | 2490 ± 59.2 | 3780 ± 29.2 | 2000 ± 29.3 |
Moxidectin concentration in plasma collected at pre-specified intervals after dosing with oral moxidectin determined using a validated liquid chromatography-mass spectrometry(MS)/MS method.
| ng/mL | 12 to 17 Years MOX 8 mg | 8 to 11 Years MOX 6 mg | 8 to 11 Years MOX 8 mg | 4 to 7 Years MOX 4 mg |
|---|---|---|---|---|
| Maximum Observed Plasma Concentrations (Cmax) of Moxidectin | 83.1 ± 19.1 | 82.1 ± 41.2 | 115 ± 25.6 | 86.4 ± 28.3 |
Incidence and severity of adverse events, assessed by the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Paediatric Adverse Events, Version 2.1.
| Participants | 12 to 17 Years MOX 8 mg | 8 to 11 Years MOX 6 mg | 8 to 11 Years MOX 8 mg | 4 to 7 Years MOX 4 mg |
|---|---|---|---|---|
| All Treatment-emergent Adverse Events (TEAEs) | 4 | 7 | 6 | 7 |
| TEAEs by Severity Grade 1 Mild | 3 | 6 | 6 | 6 |
| Grade 2 Moderate | 1 | 1 | 1 | 2 |
| Grade 3 Severe | 0 | 0 | 0 | 1 |
| Grade 4 Life-threatening | 0 | 0 | 0 | 0 |
Collected over Day 0 to 24 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 12 to 17 Years MOX 8 mg | 0/9 (0%) | 0/9 (0%) | 4/9 (44.4%) |
| 8 to 11 Years MOX 6 mg | 0/9 (0%) | 0/9 (0%) | 7/9 (77.8%) |
| 8 to 11 Years MOX 8 mg | 0/9 (0%) | 0/9 (0%) | 6/9 (66.7%) |
| 4 to 7 Years MOX 4 mg | 0/9 (0%) | 0/9 (0%) | 7/9 (77.8%) |
| Overall | 0/36 (0%) | 0/36 (0%) | 24/36 (66.7%) |
| Event | 12 to 17 Years MOX 8 mg | 8 to 11 Years MOX 6 mg | 8 to 11 Years MOX 8 mg | 4 to 7 Years MOX 4 mg | Overall |
|---|---|---|---|---|---|
| MalariaInfections and infestations | 1/9 | 5/9 | 4/9 | 4/9 | 14/36 |
| Abdominal painGastrointestinal disorders | 0/9 | 0/9 | 2/9 | 1/9 | 3/36 |
| DiarrhoeaGastrointestinal disorders | 0/9 | 2/9 | 0/9 | 1/9 | 3/36 |
| Upper respiratory tract infectionInfections and infestations | 1/9 | 1/9 | 1/9 | 0/9 | 3/36 |
| ConjunctivitisInfections and infestations | 0/9 | 1/9 | 1/9 | 0/9 | 2/36 |
| Abscess limbInfections and infestations | 0/9 | 0/9 | 0/9 | 1/9 | 1/36 |
| Hookworm infectionInfections and infestations | 0/9 | 0/9 | 0/9 | 1/9 | 1/36 |
| Tinea versicolourInfections and infestations | 1/9 | 0/9 | 0/9 | 0/9 | 1/36 |
| VomitingGastrointestinal disorders | 0/9 | 0/9 | 0/9 | 1/9 | 1/36 |
| AnaemiaBlood and lymphatic system disorders | 0/9 | 0/9 | 0/9 | 1/9 | 1/36 |
Demographic and Baseline characteristics were analyzed in the Safety Analysis Set, which included all participants who provided signed informed consent/ assent and whose eligibility was confirmed on Day 0, and the Pharmacokinetic Analysis Set, which included all participants who received moxidectin and provided a minimum number of plasma samples for the determination of PK parameters. As no subjects were excluded from any analysis set, the data within these data sets is identical.
| Age, Continuous(years) | 12 to 17 Years Moxidectin 8 mg | 8 to 11 Years Moxidectin 6 mg | 8 to 11 Years Moxidectin 8 mg | 4 to 7 Years Moxidectin 4 mg | Total |
|---|---|---|---|---|---|
| Mean | 13.7 ± 1.66 | 9.1 ± 1.05 | 9.7 ± 0.87 | 5.4 ± 1.33 | 9.5 ± 3.19 |
| Sex: Female, Male(Participants) | 12 to 17 Years Moxidectin 8 mg | 8 to 11 Years Moxidectin 6 mg | 8 to 11 Years Moxidectin 8 mg | 4 to 7 Years Moxidectin 4 mg | Total |
|---|---|---|---|---|---|
| Female | 4 | 6 | 5 | 6 | 21 |
| Male | 5 | 3 | 4 | 3 | 15 |
| Race (NIH/OMB)(Participants) | 12 to 17 Years Moxidectin 8 mg | 8 to 11 Years Moxidectin 6 mg | 8 to 11 Years Moxidectin 8 mg | 4 to 7 Years Moxidectin 4 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 9 | 9 | 9 | 9 | 36 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | 12 to 17 Years Moxidectin 8 mg | 8 to 11 Years Moxidectin 6 mg | 8 to 11 Years Moxidectin 8 mg | 4 to 7 Years Moxidectin 4 mg | Total |
|---|---|---|---|---|---|
| Ghana | 9 | 9 | 9 | 9 | 36 |
| Height(cm) | 12 to 17 Years Moxidectin 8 mg | 8 to 11 Years Moxidectin 6 mg | 8 to 11 Years Moxidectin 8 mg | 4 to 7 Years Moxidectin 4 mg | Total |
|---|---|---|---|---|---|
| Mean | 149.74 ± 10.318 | 130.09 ± 9.307 | 133.11 ± 10.590 | 108.81 ± 7.922 | 130.44 ± 17.381 |
| Weight(kg) | 12 to 17 Years Moxidectin 8 mg | 8 to 11 Years Moxidectin 6 mg | 8 to 11 Years Moxidectin 8 mg | 4 to 7 Years Moxidectin 4 mg | Total |
|---|---|---|---|---|---|
| Mean | 39.42 ± 8.754 | 25.89 ± 4.567 | 27.13 ± 4.844 | 16.90 ± 2.662 | 27.34 ± 9.766 |
| BMI(kg/m2) | 12 to 17 Years Moxidectin 8 mg | 8 to 11 Years Moxidectin 6 mg | 8 to 11 Years Moxidectin 8 mg | 4 to 7 Years Moxidectin 4 mg | Total |
|---|---|---|---|---|---|
| Mean | 17.39 ± 1.745 | 15.19 ± 1.068 | 15.23 ± 1.120 | 14.20 ± 0.919 | 15.50 ± 1.683 |
| Mean upper arm circumference at Screening(cm) | 12 to 17 Years Moxidectin 8 mg | 8 to 11 Years Moxidectin 6 mg | 8 to 11 Years Moxidectin 8 mg | 4 to 7 Years Moxidectin 4 mg | Total |
|---|---|---|---|---|---|
| Mean | 21.78 ± 2.065 | 18.42 ± 0.981 | 18.66 ± 1.591 | 15.68 ± 1.347 | 18.63 ± 2.644 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Deidentified individual participant data in the form of data listings and SDTM and ADaM datasets may be available for sharing on application to the Sponsor.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will become available 12 months after publication.
Access criteria: Provision of a methodologically sound and relevant proposal detailing the intended use of the data and relevant ethics approval for the proposed analysis, as applicable.
Ran from Mar 2021 to primary completion in May 2022, 14 months.
Results were first posted in Jan 2025, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Moxidectin
Medicines Development for Global Health